（於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 將召開及於2025年11月25日（星期二）舉行的 臨時股東大會之代表委任表格 | 與本代表委任表格 | | 內資股 | | --- | --- | --- | | 有關的股份數目 | （附註1） | H股 | 本人╱吾等 （附註2） 地址為 （地址） 為上海微創醫療機器人（集團）股份有限公司（「本公司」）已發行股本中 股內資股╱H股 （附註3） 的登記股東，茲委任大會主席 （附註4） 或 （姓名） Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 為本人╱吾等之代表，代表本人╱吾等出席本公司將於2025年11月25日（星期二）上午十時整假座中國上海市中國（上海） 自由貿易試驗區張東路1601號召開及舉行之臨時股東大會（「臨時股東大會」）或其任何續會，就有關日期為2025年11月5 日之臨時股東大會通告所載決議案按有關指示代為投票。如未作出任何指示，則按本人╱吾等之受委代表酌情決定投票。 | | 普通決議案 | （附註5） 贊成 | （附註5） 反對 | （附註 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 將於2025年11月25日（星期二）召開及舉行的 臨時股東大會通告 茲通告上海微創醫療機器人（集團）股份有限公司（「本公司」）謹訂於2025年11月25 日（星期二）上午十時整於中國上海市中國（上海）自由貿易試驗區張東路1601號召開及 舉行臨時股東大會（「臨時股東大會」），以處理下列事項。除文義另有所指外，本通告 所用詞彙與本公司日期為2025年11月5日的通函（「通函」）所界定者具有相同涵義： 普通決議案 – 1 – 1. 考慮及批准委任常兆華博士為本公司非執行董事，並授權董事會釐定其酬金。 2. 考慮及批准委任白藤泰司先生為本公司非執行董事，並授權董事會釐定其酬 金。 3. 考慮及批准委 ...

此乃要件 請即處理 閣下如對本通函任何方面或 閣下應採取的行動有任何疑問，應諮詢 閣下的持牌證券交易商或註 冊證券機構、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下的上海微創醫療機器人（集團）股份有限公司股份，應立即將本通函連 同隨附的代表委任表格送交買主或承讓人或經手買賣或轉讓的銀行、持牌證券交易商或註冊證券機 構或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. (1) 建議委任董事； (2) 建議修訂組織章程細則及 股東大會議事規則； 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 及 （股份代號：2252） (3) 臨時股東大會通告 除文義另有所指外，本封面所用詞彙與本通函「釋義」一節所界定者具有相同涵義。 謹訂於2025年11月25日（星期二）上午十時整於 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 董事變動 及 建議修訂組織章程細則及股東大會議事規則 董事變動 上海微創醫療機器人（集團）股份有限公司（「本公司」）董事會（「董事會」）謹此 宣佈董事會成員變動如下： 董事辭任 建議委任非執行董事 董事會決議提名常兆華博士（「常博士」）、白藤泰司先生（「白藤先生」）、蘆田典 裕先生（「蘆田先生」）、梁敏女士（「梁女士」）為本公司非執行董事。建議委任常 博士、白藤先生、蘆田先生、梁女士為本公司非執行董事須待本公司股東於臨 時股東大會上審議及批准。 常博士、白藤先生、蘆田先生及梁女士之履歷詳情載列如下： 常兆華博士 常兆華博士，62歲。常博士在醫療器械行業擁有逾34年的經驗，現時擔任微創 醫療科學有限公司（「 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 RMB | | 1 | RMB | | 6,599,543 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 ...

自願性公告 — 圖邁全球訂單逾百台 本公告由上海微創醫療機器人（集團）股份有限公司（「本公司」，連同其附屬公 司統稱為「本集團」）自願作出，以向本公司股東（「股東」）及潛在投資者提供有 關本集團的最新業務進展情況。 根據本集團內部初步統計數據，截至本公告日期，本集團旗下腔鏡、骨科、血 管介入核心產品的綜合訂單量累計突破170台，其中，核心產品圖邁腔鏡手術 機器人（「圖邁」）於全球範圍內累計商業化訂單超過百台，圖邁全球已裝機近 80台，穩居國產品牌首位，商業化進程已進入全面加速的階段。 基於本集團結合機器人和遠程技術構建的突破性創新生態體系，圖邁正在加 速滿足全球市場多層級臨床需求，截至本公告日期，圖邁全球人體臨床手術量 已累計突破15,000例。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上海微創醫療機器人（ 集 團 ）股份有限公司 （於中華人民共和國註冊成 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 上海微创医疗机器人（集团）股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 6,599,543 | RMB | | 1 | RMB | | 6,599,543 | | ...

Financial Performance - The company reported revenue of RMB 175.7 million for the first half of 2025, a significant increase of 77% year-over-year, driven by rapid commercialization across all product lines, particularly in overseas markets which saw a 189% increase[17]. - The company achieved a pre-tax loss of RMB 114.9 million for the first half of 2025, a significant reduction from a loss of RMB 279.9 million in the same period of 2024[10]. - The net loss for the company has significantly narrowed by 59% year-on-year, while free cash flow outflow decreased by 43% compared to the previous year, indicating improved financial health[20]. - The company recorded revenue of RMB 175.7 million for the reporting period, representing a 77% increase from RMB 99.2 million in the previous year[33]. - Overseas sales revenue reached RMB 102.4 million, marking a significant year-on-year growth of 189%[34]. - The company recorded a net gain of RMB 4.3 million from financial instruments at fair value for the six months ended June 30, 2025, compared to a net loss of RMB 10.4 million for the same period in 2024[94]. - The company achieved a net profit of RMB 3.0 million from equity-accounted investees for the six months ended June 30, 2025, compared to a net loss of RMB 9.8 million for the same period in 2024, driven by the commercialization of the vascular interventional robot R-ONE[96]. - For the six months ended June 30, 2025, the adjusted net loss was RMB 97.1 million, a significant improvement from the adjusted net loss of RMB 218.4 million for the same period in 2024[100]. - The company reported a loss of RMB 114,923 thousand for the six months ended June 30, 2025, compared to a loss of RMB 279,950 thousand in the same period of 2024, indicating a significant improvement[200]. - Total comprehensive income for the period was RMB (114,541) thousand, an improvement from RMB (280,020) thousand year-over-year[200]. Operational Efficiency - The company continues to focus on operational efficiency and cost reduction measures, which contributed to a significant decrease in losses during the reporting period[16]. - Sales and marketing expenses decreased by 12.8% to RMB 80.4 million for the six months ended June 30, 2025, from RMB 92.2 million for the same period in 2024, with the expense ratio dropping from 93% to 46% of operating revenue[88]. - Administrative expenses fell by 40.0% to RMB 18.1 million for the six months ended June 30, 2025, down from RMB 30.1 million for the same period in 2024, due to ongoing improvements in operational efficiency[90]. - R&D costs decreased by 46.0% to RMB 88.6 million for the six months ended June 30, 2025, from RMB 164.1 million for the same period in 2024, as the company focused on optimizing the performance of commercialized products[91]. - The company is focused on enhancing operational efficiency and optimizing production processes to improve cost control and cash flow management[33]. Product Development and Market Expansion - The company is recognized as the only surgical robot company globally with a comprehensive portfolio covering five major fields: laparoscopic, orthopedic, vascular, natural orifice, and percutaneous procedures[12]. - The company aims to build a global medical robot innovation platform to provide comprehensive robotic surgical solutions that extend and reshape lives[13]. - The company has successfully expanded its overseas market presence, securing over 30 orders and completing installations of 16 units, bringing the total overseas installations to 27[19]. - The cumulative commercial orders for the company's laparoscopic, orthopedic, and vascular intervention core products reached nearly 150 units, with over 100 units commercialized globally[34]. - The company has achieved over 30 registrations in various countries or regions, enhancing its competitiveness in international markets[37]. - The flagship product, Honghu, has accumulated over 55 global orders, covering medical institutions across five continents[34]. - The company is actively promoting the development of high-end medical equipment in overseas markets as part of the "Belt and Road" initiative[31]. - The company aims to leverage its diverse product portfolio and continuous innovation to meet the growing clinical demands of global doctors and patients, amidst increasing industry competition[24]. Clinical Achievements - The total number of clinical surgeries using the company's robotic systems has surpassed 12,000 globally, with a notable 1,000 surgeries performed at Shanghai Pulmonary Hospital alone[21]. - The company has implemented nearly 500 remote surgeries, setting over 50 world records, and has become the first globally approved remote surgical robot, enhancing its technological leadership[23]. - The company has successfully completed over 100 vascular intervention robot surgeries, gaining widespread clinical recognition[37]. - The company has established the largest global remote surgery network, achieving full coverage of domestic multi-level remote surgery networks and gradually expanding cross-national and cross-continental coverage[39]. - The cumulative clinical applications of "Honghu" cover 75 domestic hospitals and 25 hospitals in Europe and the United States, with nearly 2,500 completed surgeries[63]. Financial Position and Assets - Total assets increased to RMB 1,499.8 million as of June 30, 2025, compared to RMB 1,279.0 million at the end of 2024, reflecting strong growth in current assets[11]. - The company’s total equity rose to RMB 513.8 million as of June 30, 2025, up from RMB 257.7 million at the end of 2024, indicating improved financial health[11]. - The company's cash and cash equivalents increased from RMB 612.2 million as of December 31, 2024, to RMB 815.8 million as of June 30, 2025, primarily due to H-share placement[110]. - The total interest-bearing borrowings as of June 30, 2025, were RMB 632.9 million, a slight decrease from RMB 634.5 million as of December 31, 2024[114]. - The company's asset-liability ratio improved to 66% as of June 30, 2025, down from 80% as of December 31, 2024[114]. - The net current asset value increased to RMB 454.9 million as of June 30, 2025, compared to RMB 353.1 million as of December 31, 2024, attributed to H-share placement and commercialization progress[115]. Shareholder Information and Corporate Governance - The company aims to achieve a high level of corporate governance, which is crucial for development and safeguarding shareholder interests[171]. - The company confirmed compliance with the standard code of conduct for securities trading by all directors and supervisors during the reporting period[155]. - The company has not reported any significant changes to the planned use of proceeds from the December 2024 and May 2025 placements as of June 30, 2025[127][132]. - The company has adopted a stock option plan to incentivize qualified individuals contributing to the group's development[164]. - The share incentive plan allows for a maximum of 10% of the issued H shares to be awarded, equating to 95,199,428 H shares, approximately 9.93% of the company's issued capital as of the report date[161].

Investment Rating - The report assigns an "Accumulate" rating to the company, indicating a positive outlook for the stock over the next six months [4][6]. Core Insights - The company has experienced a significant revenue increase of 77.04% year-on-year, reaching 176 million yuan, while also reducing losses compared to the previous year [1][2]. - The gross profit margin stands at 40.70%, with a notable improvement in operational efficiency due to cost optimization and scale effects [2]. - The company is benefiting from strong growth in overseas markets, with substantial increases in revenue from regions outside of China, particularly in the Asia-Pacific and Europe [3]. - The product pipeline is expanding, with key products receiving regulatory approvals, enhancing the company's competitive position in the market [3]. Financial Summary - Revenue projections for 2025-2027 are estimated at 493 million, 844 million, and 1.193 billion yuan, respectively, with a gradual improvement in net profit expected [4][5]. - The company is expected to achieve a net profit of 125 million yuan by 2027, reflecting a significant turnaround from previous losses [5][10]. - The financial metrics indicate a strong growth trajectory, with revenue growth rates projected at 384.15% for 2024 and 91.50% for 2025 [5][10]. Market Performance - The stock has shown impressive absolute returns of 294% over the past 12 months, outperforming the market significantly [8]. - The company's market capitalization is approximately 30 billion HKD, with a current share price of 29.10 HKD [6][8].

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company achieved a revenue of 176 million yuan in H1 2025, representing a year-on-year growth of 77%, with overseas market revenue growing by 189%. The net loss was 115 million yuan, a significant reduction of 58.9%. The expectation is for continued high growth in revenue due to new product launches and accelerated overseas expansion in 2025 [1][2][4]. Summary by Sections Growth Potential - The company is expected to experience high revenue growth in 2025 driven by both domestic and overseas markets. Overseas orders have seen rapid growth, with over 80 commercial orders and more than 60 installations globally. The company has received CE certification for its surgical robots, allowing for expansion into various surgical fields [2][3]. - The domestic market is also poised for growth as the National Health Commission has increased the number of approved laparoscopic surgical systems significantly, which is expected to boost installations [2]. - New products are being commercialized, including a single-port surgical robot and a remote surgical robot, enhancing market competitiveness [2][3]. Profitability - The company reported a net loss of 115 million yuan in H1 2025, a reduction of 58.9%. With ongoing product rollouts and improved management, the expense ratio is expected to decline, leading to further narrowing of losses in 2025 [4]. Financial Forecast and Valuation - Revenue projections for 2025-2027 are 480 million, 885 million, and 1.302 billion yuan, with year-on-year growth rates of 86.55%, 84.38%, and 47.11% respectively. The expected net profit for 2025 is projected at -258 million yuan, with an EPS of -0.25 yuan [5][11].